Buccal Drug Delivery Systems Market Analysis: Global Industry Size, Growth and Forecast
Report ID : 1299307 | Published : April 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Buccal Drug Delivery Systems Market is categorized based on Formulation Type (Tablets, Films, Gels, Sprays, Others) and Route of Administration (Sublingual, Buccal, Others) and End User (Hospitals, Homecare, Pharmacies, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
Valued at $3.5 billion in 2023, the Buccal Drug Delivery Systems Market size is expected to grow to $7.2 billion by 2033, with a CAGR of 7.5% from 2024 to 2033. The report comprises various segments and analyzes the trends and factors playing a substantial role in the market.
The Buccal Drug Delivery Systems Market is growing rapidly as more and more pharmaceutical companies appreciate the advantages associated with non-invasive drug delivery techniques. These systems facilitate delivery of drugs through the buccal mucosa which makes it possible for the drug to be absorbed directly into the bloodstream, thus avoiding the gastrointestinal tract and liver metabolism. This novel technique not only improves bioavailability but also aids in greater patient adherence, especially among those who have difficulty swallowing conventional tablets or need rapid therapeutic effects.
Due to the rising demand for enhanced, efficient as well as patient-friendly drug delivery systems, the buccal route is gaining attention, particularly for use in pain management, hormonal therapies, and various neurological conditions. The market is diverse with varying products like films and tablets, and even sprays and gels, all aimed at meeting the demands of patients and healthcare practitioners. The Buccal Drug Delivery Systems Market is set to face substantial advancements in the years to come due to new technologies in formulation development, increased focus on personalized medicine, and shifting expectations towards drug delivery systems, which will change the future of medication administration.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Indivior PLC, BioDelivery Sciences International Inc., Boehringer Ingelheim GmbH, Sorrento Therapeutics Inc., Roche Holding AG, Purdue Pharma L.P., GSK (GlaxoSmithKline) PLC, Eli Lilly and Company, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V. |
| SEGMENTS COVERED |
By Formulation Type - Tablets, Films, Gels, Sprays, Others
By Route of Administration - Sublingual, Buccal, Others
By End User - Hospitals, Homecare, Pharmacies, Others
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Buccal Drug Delivery Systems Market Dynamics
The Buccal Drug Delivery Systems Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Buccal Drug Delivery Systems Market Segmentations
Market Breakup by Formulation Type
- Overview
- Tablets
- Films
- Gels
- Sprays
- Others
Market Breakup by Route of Administration
- Overview
- Sublingual
- Buccal
- Others
Market Breakup by End User
- Overview
- Hospitals
- Homecare
- Pharmacies
- Others
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Buccal Drug Delivery Systems Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Indivior PLC
- BioDelivery Sciences International Inc.
- Boehringer Ingelheim GmbH
- Sorrento Therapeutics Inc.
- Roche Holding AG
- Purdue Pharma L.P.
- GSK (GlaxoSmithKline) PLC
- Eli Lilly and Company
- AstraZeneca PLC
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved